TY - JOUR
T1 - Incidence, Prevalence, and Mortality of Lupus Nephritis
T2 - A Population-Based Study Over Four Decades Using the Lupus Midwest Network
AU - Hocaoǧlu, Mehmet
AU - Valenzuela-Almada, Maria O.
AU - Dabit, Jesse Y.
AU - Osei-Onomah, Shirley Ann
AU - Chevet, Baptiste
AU - Giblon, Rachel E.
AU - Zand, Ladan
AU - Fervenza, Fernando C.
AU - Helmick, Charles G.
AU - Crowson, Cynthia S.
AU - Duarte-García, Alí
N1 - Publisher Copyright:
© 2022 American College of Rheumatology.
PY - 2023/4
Y1 - 2023/4
N2 - Objective: There is a paucity of population-based studies investigating the epidemiology of lupus nephritis (LN) in the US and long-term secular trends of the disease and its outcomes. We aimed to examine the epidemiology of LN in a well-defined 8-county region in the US. Methods: Patients with incident LN between 1976 and 2018 in Olmsted County, Minnesota (1976–2009) and an 8-county region in southeast Minnesota (2010–2018) were identified. Age- and sex-specific incidence rates and point prevalence over 4 decades, adjusted to the projected 2000 US population, were determined. Standardized mortality ratios (SMRs), survival rates, and time to end-stage renal disease (ESRD) were estimated. Results: There were 72 patients with incident LN between 1976 and 2018, of whom 76% were female and 69% were non-Hispanic White. Mean ± SD age at diagnosis was 38.4 ± 16.24 years. Average annual LN incidence per 100,000 population between 1976 and 2018 was 1.0 (95% CI 0.8–1.3) and was highest in patients ages 30–39 years. Between the 1976–1989 and 2000–2018 time periods, overall incidence of LN increased from 0.7 to 1.3 per 100,000, but this was not statistically significant. Estimated LN prevalence increased from 16.8 per 100,000 in 1985 to 21.2 per 100,000 in 2015. Patients with LN had an SMR of 6.33 (95% CI 3.81–9.89), with no improvement in the mortality gap in the last 4 decades. At 10 years, survival was 70%, and 13% of LN patients had ESRD. Conclusion: The incidence and prevalence of LN in this area increased in the last 4 decades. LN patients have poor outcomes, with high rates of ESRD and mortality rates 6 times that of the general population.
AB - Objective: There is a paucity of population-based studies investigating the epidemiology of lupus nephritis (LN) in the US and long-term secular trends of the disease and its outcomes. We aimed to examine the epidemiology of LN in a well-defined 8-county region in the US. Methods: Patients with incident LN between 1976 and 2018 in Olmsted County, Minnesota (1976–2009) and an 8-county region in southeast Minnesota (2010–2018) were identified. Age- and sex-specific incidence rates and point prevalence over 4 decades, adjusted to the projected 2000 US population, were determined. Standardized mortality ratios (SMRs), survival rates, and time to end-stage renal disease (ESRD) were estimated. Results: There were 72 patients with incident LN between 1976 and 2018, of whom 76% were female and 69% were non-Hispanic White. Mean ± SD age at diagnosis was 38.4 ± 16.24 years. Average annual LN incidence per 100,000 population between 1976 and 2018 was 1.0 (95% CI 0.8–1.3) and was highest in patients ages 30–39 years. Between the 1976–1989 and 2000–2018 time periods, overall incidence of LN increased from 0.7 to 1.3 per 100,000, but this was not statistically significant. Estimated LN prevalence increased from 16.8 per 100,000 in 1985 to 21.2 per 100,000 in 2015. Patients with LN had an SMR of 6.33 (95% CI 3.81–9.89), with no improvement in the mortality gap in the last 4 decades. At 10 years, survival was 70%, and 13% of LN patients had ESRD. Conclusion: The incidence and prevalence of LN in this area increased in the last 4 decades. LN patients have poor outcomes, with high rates of ESRD and mortality rates 6 times that of the general population.
UR - http://www.scopus.com/inward/record.url?scp=85146274375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146274375&partnerID=8YFLogxK
U2 - 10.1002/art.42375
DO - 10.1002/art.42375
M3 - Article
C2 - 36227575
AN - SCOPUS:85146274375
SN - 2326-5191
VL - 75
SP - 567
EP - 573
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 4
ER -